1. Urinary kallikrein, renal tissue kininogenase activity, and plasma kininogen were measured during the development of hypertension in rats, either with left renal artery clamped and contralateral kidney intact (Goldblatt 2-kidney) or removed (Goldblatt 1-kidney). Plasma urea, plasma volume and blood volume were also measured.
Introduction
Clamping one renal artery induces hypertension in rats whether or not the contralateral kidney is present. Renin concentration in plasma increases when the unclamped kidney is left in situ although it remains within normal values when the intact kidney is removed (Hutchinson, Mathews, Dax & Johnston, 1975) . It has been suggested that two different mechanisms may be involved in the development and maintenance of these two types of renal hypertension and that the renin-angiotensin system plays an important role only in the first type (Swales, Thurston, Queiroz, Medina & Holland, 1971; Brunner, Kirshman, Sealey & Laragh, 1971) . As an alternative hypothesis it has been proposed that blood pressure elevation results from the loss of a renal antihypertensive factor. Thus, there is evidence that renal prostaglandins (Lee, Covino, Takman & Smith, 1965) , renomedullary neutral lipid (Muirhead, Brooks, Kosinksi, Daniels & Hinman, 1966) and renal kallikrein (Croxatto, Roblero, Albertini, Corthorn & San Martin, 1974a) could be effective humoral vasodepressor factors. The renal kallikrein system has been implicated in the development of hypertension on several groups: (a) the decrease of urinary kallikrein excretion in different types of clinical, spontaneous and experimental hypertension (Margolius, Harwitz, Pisano & Keiser, 1974; Porcelli, Bianchi & Croxatto, 1975; Croxatto & San Martin, 1970) ; (b) the significant fall of kidney kallikrein in experimental hypertension associated with normal or low plasma renins (Croxatto, Albertini, Roblero & Corthorn, 19746) ; and (c) the increase in plasma kininogen in experimental hypertension (Albertini, Roblero, Corthorn & Croxatto, 1974) . Further, the natriuretic-diuretic actions of kinins (Carretero & Oza, 1973; Mills & Ward, 1975) , and the rapid response of renal kallikrein under conditions requiring acceleration of water and electrolyte excretion (Croxatto, Huidobro, Rojas, Roblero & Albertini, 1976a) provide further experimental support for the concept that renal kallikrein may be an important antihypertensive factor.
The purpose of the present study is to characterize changes in the kallikrein-kinin system during the development of renovascular hypertension. Thus the amount of kallikrein excreted, the kininogenase capacity of renal tissue and the total amount of plasma substrate in Goldblatt I-kidney and 2-kidney hypertensive rats were examined. The relationship between the kallikrein-kinin system and kidney excretory function was also studied by measuring urinary volume, sodium (UNa+) and potassium (UK+) excretion, plasma urea, plasma volume and blood volume.
Method
Hypertension was induced in male SpragueDawley rats, weighing between 90 and 100 g, by placing a silver clamp (internal gap 0.23 mm) around the left renal artery: the contralateral kidney was left intact (Goldblatt 2-kidney, G-2 rats) or removed a week later (Goldblatt 1-kidney, G-1 rats). Sham-clamped two-kidney and onekidney rats were used as controls for the G-2 rats and G-1 rats respectively. These surgical procedures were performed under tribromoethanol (Avertin, Winthrop) given intraperitoneally (20 mg/ 100 g body wt.).
Tail blood pressure was measured weekly, under light ether anaesthesia at room temperature. The pressure on the tail cuff and the tail artery pulse were registered simultaneously on a Grass pulse detector. The G-2 rats and the two-kidney control rats were killed at 35, 74 and 115 days after clamping. The G-1 rats and the one-kidney control rats were killed at 35 and 74 days after clamping.
The day before the final experiment, urine was collected and blood pressure was assessed in hypertensive and control groups. Some G-2 rats and two-kidney control rats, selected at random, were used for urine collection every week, starting at the first week after clamping.
Urine was collected by placing the rats in individual metabolic cages for 8 h, without food and with tap water ad libitum. Toluene (1 ml) as antiseptic was added to each container. Urine volume was measured and urine samples were kept frozen at -2OOC for subsequent determination of kallikrein activity and electrolytes.
Urinary kallikrein was measured in most of the rats by either the direct oxytocic activity on rat uterus (Beraldo, Rocival & Mares Guia, 1966; Croxatto & No6, 1972) or by kinin generation (Croxatto & Noe, 1972; Croxatto, San Martin & Roblero, 1972) . Because there was good correlation between values by both methods (r = 0.83) only the data derived by the direct oxytocic effect of the urine are reported in this study. Before the determination, urine samples were dialysed against 0.9% NaCl solution at 4OC for 24 h. A freshly prepared bradykinin solution was used as standard, and kallikrein activity was expressed as pg of bradykinin in the total volume of urine collected during an 8 h period (after dialysis). Appropriate corrections were made for dilution.
UNa+ and UK+ were determined by using an Eppendorf flame photometer.
Plasma volume was measured by a dilution-technique method. Between 11.00 hours and 15.00 hours, one control rat and one hypertensive rat were simultaneously anaesthetized with tribromoethanol and injected with 5 pCi (0.2 ml) of I3lI-labelled human serum albumin, via a PE-50 polyethylene catheter inserted into the jugular vein, and completely bled 10 min later. Blood was collected in a plastic container through a heparinized PE-90 polyethylene catheter, inserted into one carotid artery, and centrifuged at 2500 g for 20 min. A 1 ml sample of plasma was taken for the radioactivity determination against a standard in a gamma counter. Blood volume was calculated from plasma volume and packed cell volume and expressed in m1/100 g body wt. Urea was measured in plasma using the Skeggs (1957) micromethod adapted to a Technicon Autoanalyzer, and was expressed in mmol/l of plasma. Immediately after bleeding, the kidneys here removed, weighed and frozen. Kallikrcin was extracted 24 h later and the capacity of each extract to liberate kinins was tested on longitudinal cat jejunum strips, bathed in a Krebs solution. The methods of extracting kallikrein and testing the kinin-liberation capacity of kidney extracts have been previously described (Croxatto et al., 19746) .
Aprotinin (Trasylol, Bayer) was used as an inhibitor of kininogenase activity and the activity of the extracts was expressed as pg of bradykinin generated per g and per total mass of wet tissue.
Duplicate 0.2 ml samples of plasma were taken for kininogen determination. To estimate plasma kininogen, trypsin was used by the method of Fasciolo, Espada & Carretero (1963) . Instead of the hind-leg perfusion bioassay, the isolated cat jejunum was used to test kinins (Ferreira & Vane, 1967) . Kininogen was expressed as pg of bradykinin generated/ml of plasma.
SEM.
The differences in mean values were determined by Student's t-test and P < 0.05 was considered statistically significant.
All results were expressed as means

Results
Blood pressure, body weight and kidney weight are summarized in Table 1 . In G-2 rats, in spite of the small size of the clamped kidney, the total weight of renal tissue was not significantly different from that of two-kidney control rats. In G-1 rats, the clamped kidney showed a small, but significant weight loss in comparison with the kidney of the unilaterally nephrectomized control rats ( P < 0.05) 10 weeks after surgery.
Urinary kallikrein, urine volume, sodium and potassium excretion
Five weeks after clamping, urinary kallikrein of G-2 rats was not significantly different from that of control sham-operated rats, despite the fact that blood pressure was significantly elevated ( P < 0.001). However, at weeks 10 and 15, a significant decrease was observed in urinary kallikrein concentrations ( P < 0.001) (Fig. la) . In G-1 rats, urinary kallikrein was markedly decreased at weeks 5 and 10 ( P < 0.001) (Fig. lb) . Further, the values were significantly lower than those found during the same period in the urine of the G-2 rats ( P < 0.01).
Urinary kallikrein of unilaterally nephrectomized control rats was not different from that of twokidney sham-operated rats (Figs. la and lb) . Blood pressure of G-2 rats increased significantly from week 2 after the clamping (Fig. 2) . Urinary kallikrein concentration during the first 6 weeks was only slightly lower than that of the sham-operated rats. From week 8 a significant drop in urinary kallikrein concentrations was observed, continuing to fall in the subsequent weeks (Fig. 2) .
During the first 4 weeks, urine volume of the hypertensive rats was slightly lower, but this difference was not significant ( P < 0.20). From weeks 5 on, the hypertensive rats showed an increase in urine volume, which was significantly different from control rats at weeks 5 , 10 and 12 (Fig. 2) . The UNa+ and UK+ of G-2 rats and control rats showed parallel changes all during the experiment except at week 10, when G-2 rats excreted more Na+ ( P < 0.05) (Pig. 2). 
Kininogenase activity in renal tissue
When G-2 rats were compared with shamoperated rats, there was no significant difference in the total kininogenase activity or in the activity/g of wet tissue, in any of the experimental periods (Fig.  3a) .
In G-1 rats, the total kininogenase activity at weeks 5 and 10 was significantly lower than in the Plasma kininogen, plasma urea, plasma and blood volumes, in Goldblatt two-kidney (G-2) and one-kidney 
(G-I) hypertensive rats
Values are mean k SEM. Results of statistical analysis between control and experimental groups are: * P < 0.05; ** P < 0.01; *** P < 0.001. N.S. =not significant. C-2, Two-kidney control rats; C-I, one-kidney control rats.
unilaterally nephrectomized control rats. The activity/g was also significantly reduced ( P < 0.001) (Fig. 3b) . In the unilaterally nephrectomized control group, the total kininogenase activity was not different from the activity found in the shamoperated two-kidney group, but was significantly higher/g of wet tissue in each experimental period ( P < 0.001 at week 5 and P < 0.05 at week 10) (Figs. 3a and 3b) . Aprotinin (200 units) completely abolished the kininogenase activity of the kidney extracts. No significant differences in kininogenase activity were found between the clamped kidney and the intact kidney in G-2 rats. The amounts of kinin liberated were 2.48 f 0.24 in the intact kidney against 1-99 & 0.12 pg of bradykiin/g in the clamped kidney, 1.86 f 0.17 against 1.73 k 0.08 pg of bradykinidg and 1.77 f 0.14 against 1.73 f 0-20 pg of bradykmin/g at weeks 5, 10 and 15 respectively. Plasma kininogen, plasma urea, plasma and blood volumes Plasma substrate was significantly increased in both types of hypertensive rats at weeks 5 and 10, compared with the control groups. Nevertheless, in the G-2 rats, plasma kiniiogen concentrations diminished gradually with time and reached control values by week 15 (Table 2) .
A similar pattern was observed in plasma urea, plasma volume and blood volume in G-2 rats. At week 5, there were no significantdifferences, but by week 10 plasma urea, plasma volume and blood volume increased compared with controls. This increment persisted until the end of the experiment.
All three were increased in G-1 rats by week 5 and remained high at week 10 ( Table 2 ).
Discussion
Our results show important differences between G-1 and G-2 hypertensive rats, with regard to the time-course and patterns of changes in urinary and renal kallikrein concentrations, plasma kininogen concentrations, and plasma and blood volumes. Urinary kallikrein falls rapidly in both Wistar and Sprague-Dawley rats, made hypertensive by placing a figure eight ligature on one kidney followed by contralateral nephrectomy (Croxatto & San Martin, 1970) . Margolius, Geller, Pisano & Sjoerdsma (1971) confirmed the fall of urinary kallikrein concentration in rats made hypertensive by placing a silver clamp on one renal artery while leaving the contralateral kidney intact (G-2). They measured urinary kallikrein only at week 16 after clamping and did not follow its time course during the onset and development of hypertension. Johnston, Matthews & Dax (1976) reported normal kallikrein excretion by G-1 rats and increased kallikrein excretion by G-2 rats, at least until the 28th post-operative day. In the present study, as early as 5 weeks after clamping, in G-1 rats a large fall in urinary kallikrein concentration was observed; in contrast, at this time G-2 rats had values similar to the sham-operated control. We cannot explain the discrepancy between our fmdings and those of Johnston et al. (1976) .
The concept that the renal kallikrein-kinin system participates in the regulation of extracellular fluid volume by control of water excretion has been suggested by Mills & Ward (1975) . We have previously showed that water-loading, as well as sodium chloride loading (Croxatto et al., 1976a) and administration of diuretics (Croxatto, Roblero, Garcia, Corthorn & San Martin, 1973) produce increased kallikrein excretion in normal rats. In G-1 rats, which show reduced urinary kallikrein, only a moderate increase in the urinary excretion of this enzyme is observed when diuresis is stimulated by water (Croxatto, Albertini, Arriagada, Roblero, Rojas & Rosas, 1976b) . These observations support the concept that the stimuli which increase diuresis and natriuresis promote an activation of the renal kallikrein-kinin system. They also support the idea that this system is markedly impaired in G-1 rats. This impairment is also observed in G-2 rats, but only after long-term hypertension, apparently when plasma and blood volume are incqeased. In addition, in unilaterally nephrectomized control rats, the decrease in kidney mass promoted an increase in the renal kininogenase activity/g of wet tissue. This compensatory mechanism is not present in G-1 rats, and may be related to the increase in plasma volume found in the early phase of this model of experimental hypertension.
The increase in plasma kininogen has been utilized as evidence for the involvement of the kallikrein-kinin system in hypertension (Croxatto, Corthorn, Roblero, Garcia & Albertini, 1974~) . The persistent high concentration of plasma kininogen and the low kallikrein activity found in renal tissue and urine, support the idea that the substrate concentration in G-1 rats hypertension might reflect enzymic activity. However, the high concentration of plasma kiniinogen with normal kininogenase activity in renal tissue and urine in G-2 rats is not consistent with this hypothesis. Wong, Talamo, Williams & Colman (1975) demonstrated that in normal subjects plasma angiotensin I1 and bradykiniin exhibit parallel changes, when saline is infused or body position modified. The response to an angiotensin I1 antagonist suggests that in G-2 rats the reninangiotensin system is hyperactive (Brunner et al., 197 1) . Therefore, the components of the kallikreinkinin system could also be stimulated.
The decrease of renal kininogenase activity in G-1 rats agrees with previous reports (Croxatto ef al., 19746) but our findings are in contrast with those of Carretero, Oza, Scicli & Schork (1974) , who described a fall in renal-cortex kallikrein in G-2 rats 36 days after renal clamping. Only one rat at the 5th week, two rats at the loth week and two rats at the 15th week in our experimental series showed lower renal kininogenase activity than the mean values found in sham-operated rats. The findings by Carretero et al. (1974) that both clamped and unclamped kidneys in G-2 rats have similar kallikrein concentrations were confirmed.
Our results, which provide data only about kininogen in blood, kallikrein in urine and kininogenase activity of the kidneys, are not sufficient to assign to the kallikrein-kinin system a causative role in hypertension. Before ruling out the involvement of this system in the etiology of hypertension, including essential hypertension, it would be necessary to assess whether renal kallikrein is contributing to kinin formation in the blood or participating, through kinin formation, in renal function.
